相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Kupffer cell activation is a causal factor for hepatic insulin resistance
Nicolas Lanthier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2010)
Depletion of Liver Kupffer Cells Prevents the Development of Diet-Induced Hepatic Steatosis and Insulin Resistance
Wan Huang et al.
DIABETES (2010)
Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
Elisa Fabbrini et al.
HEPATOLOGY (2010)
Kupffer Cells Promote Hepatic Steatosis Via Interleukin-1β-Dependent Suppression of Peroxisome Proliferator-Activated Receptor α Activity
Rinke Stienstra et al.
HEPATOLOGY (2010)
Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) Extension Trial
Vlad Ratziu et al.
HEPATOLOGY (2010)
5-Lipoxygenase Deficiency Reduces Hepatic Inflammation and Tumor Necrosis Factor α-Induced Hepatocyte Damage in Hyperlipidemia-Prone ApoE-Null Mice
Marcos Martinez-Clemente et al.
HEPATOLOGY (2010)
Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro
Jun Yu et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
Histopathology of nonalcoholic fatty liver disease
Elizabeth M. Brunt et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling
Alicia H. Clementi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2009)
PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
Shigeki Sugii et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
An in vitro method of alcoholic liver injury using precision-cut liver slices from rats
Lynell W. Klassen et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial
Vlad Ratziu et al.
GASTROENTEROLOGY (2008)
Fat paradox of steatohepatitis
Hidekazu Tsukamoto et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2008)
Abnormalities of Lipid Metabolism in Nonalcoholic Fatty Liver Disease
Onpan Cheung et al.
SEMINARS IN LIVER DISEASE (2008)
Mechanisms of Disease Progression in Nonalcoholic Fatty Liver Disease
Janice Jou et al.
SEMINARS IN LIVER DISEASE (2008)
Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones
Andrea L. Hevener et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Genetic Manipulations of PPARs: Effects on Obesity and Metabolic Disease
Yaacov Barak et al.
PPAR RESEARCH (2007)
Aberrant hepatic expression of PPARγ2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis
Yuan-Li Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Acetaldehyde inhibits PPARγ via H2O2-mediated c-Abl activation in human hepatic stellate cells
Elisabetta Ceni et al.
GASTROENTEROLOGY (2006)
Insulin and oleic acid increase PPARγ2 expression in cultured mouse hepatocytes
U Edvardsson et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes
SE Schadinger et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARγ activation
A Planagumà et al.
FASEB JOURNAL (2005)
Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle
WM He et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Muscle-specific Pparg deletion causes insulin resistance
AL Hevener et al.
NATURE MEDICINE (2003)
Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass
O Gavrilova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-γ, pioglitazone
N Enomoto et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
K Matsusue et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression
ST Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Nuclear receptors and lipid physiology: Opening the X-files
A Chawla et al.
SCIENCE (2001)
Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones
M Bedoucha et al.
JOURNAL OF HEPATOLOGY (2001)
Hepatic over-expression of peroxisome proliferator activated receptor gamma 2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus
R Rahimian et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2001)
Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists
JM Olefsky
JOURNAL OF CLINICAL INVESTIGATION (2000)
Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells
F Marra et al.
GASTROENTEROLOGY (2000)
Roles of PPARs in health and disease
S Kersten et al.
NATURE (2000)
分享论文
